On Air Now

Listen

Listen Live Now » 98.5 FM Battle Creek, Michigan

Weather

Current Conditions(Battle Creek,MI 49017)

More Weather »
66° Feels Like: 66°
Wind: WSW 7 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Isolated Thunderstorms 52°

Tomorrow

Isolated Thunderstorms 79°

Fri Night

Isolated Thunderstorms 60°

Alerts

EU agency recommends new drugs from Roche, Biogen and PTC

LONDON (Reuters) - European regulators said on Friday they had recommended approval of Roche's drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukemia, boosting the Swiss group's line-up of new cancer treatments.

The new medicine is an improved follow-on medicine to Roche's $7 billion-a-year Rituxan, or MabThera, and Roche is hoping to switch as many patients as possible to the newer product before Rituxan faces competition from cheaper copies.

The European Medicines Agency also gave a green light to Biogen Idec's Plegridy for multiple sclerosis and a recommendation for conditional approval to PTC Therapeutics' Translarna for Duchenne muscular dystrophy.

Shares in PTC soared on the green light.

Novartis received a mixed bag of news, with its Alcon eyecare unit winning a recommendation for Simbrinza, a treatment for open-angle glaucoma or ocular hypertension, but heart treatment serelaxin was rebuffed once again following further re-examination by EU experts.

Recommendations for marketing approval by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

(Reporting by Ben Hirschler; Editing by Paul Sandle, Greg Mahlich)

Comments